---
title: "EyePoint Stockholders Approve Incentive Plan and Board Slate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290429482.md"
description: "EyePoint Pharmaceuticals stockholders approved amendments to its Long-Term Incentive Plan, adding 4.9 million shares for equity awards, and re-elected all nominated directors. The meeting also saw approval of executive compensation and the ratification of Deloitte & Touche LLP as auditor. Analysts maintain a 'Buy' rating with a $43 price target, while TipRanks' AI analyst rates the stock 'Neutral' due to weak financial performance despite pipeline support."
datetime: "2026-06-22T11:38:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290429482.md)
  - [en](https://longbridge.com/en/news/290429482.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290429482.md)
---

# EyePoint Stockholders Approve Incentive Plan and Board Slate

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

The latest update is out from EyePoint Pharmaceuticals ( (EYPT) ).

EyePoint, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026 via live webcast, with a quorum of 84.74% of the 83,795,203 eligible common shares participating. Stockholders approved an amendment to the 2023 Long-Term Incentive Plan to add 4.9 million shares for equity awards, reinforcing the company’s ability to use stock-based incentives in its compensation programs.

At the meeting, investors re-elected all nominated directors to serve until the 2027 annual meeting, signaling continuity in the company’s board leadership. Stockholders also backed, on an advisory basis, the compensation of named executive officers and ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, underscoring broad support for current governance and financial oversight practices.

The most recent analyst rating on (EYPT) stock is a Buy  
with a $43.00 price target.  
To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock,  
see the EYPT Stock Forecast page.

**Spark’s Take on EYPT Stock**

According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.

Overall score reflects weak financial performance dominated by sharp revenue contraction, large operating losses, and significant cash burn. Pipeline updates and reiterated runway into Q4 2027 provide meaningful support, but the stock’s technical setup remains below key moving averages with negative MACD, and valuation metrics are constrained by negative earnings and no dividend yield data.

To see Spark’s full report on EYPT stock,  
click here.

**More about EyePoint Pharmaceuticals**

EyePoint, Inc. operates in the pharmaceutical and biotechnology industry, focusing on developing and commercializing therapeutics, with its capital structure anchored in common stock held by a broad base of stockholders. The company relies on long-term incentive plans and equity-based compensation to attract and retain executives and directors as part of its corporate governance and talent strategy.

**Average Trading Volume:** 958,269

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $1.14B

Find detailed analytics on EYPT stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)

## Related News & Research

- [Did EyePoint's (EYPT) Federal Settlement and 5‑Year Integrity Deal Just Reframe Its Risk Profile?](https://longbridge.com/en/news/294025728.md)
- [Swiss National Bank Takes Position in Eyepoint Pharmaceuticals, Inc. $EYPT](https://longbridge.com/en/news/294482810.md)
- [Is Toast stock a bargain AI play after its latest revenue surge?](https://longbridge.com/en/news/295324353.md)
- [Lionsgate Stock (LION) Falls as Report Flags Activist Push to Sell the Business](https://longbridge.com/en/news/295561405.md)
- [Hims & Hers Q2 Earnings Preview: Options Traders Brace for a 14.5% Move in HIMS Stock](https://longbridge.com/en/news/295308959.md)